Abstract
Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if ≥ 10 pg/ml. We identified 69 patients with median age of 34 years (range 16-74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and β 2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57%, 36%, and 7% of the population, and their 5-year PFS was 80%, 63%, and 0%, respectively (P <0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.
| Original language | English |
|---|---|
| Pages (from-to) | 2085-2092 |
| Number of pages | 8 |
| Journal | Leukemia and Lymphoma |
| Volume | 45 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2004 |
Fingerprint
Keywords
- Hodgkin's disease
- Interleukin-10
- Prognostic factors
- Radiotherapy
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. / Visco, Carlo; Vassilakopoulos, Theodoros P.; Kliche, Kay Oliver; Nadali, Gianpaolo; Viviani, Simonetta; Bonfante, Valeria; Medeiros, L. Jeffrey; Notti, P.; Rassidakis, George Z.; Peethambaram, Prema; Wilder, Richard; Witzig, Thomas; Gianni, Massimo; Bonadonna, Gianni; Pizzolo, Giovanni; Pangalis, Gerassimos A.; Cabanillas, Fernando; Sarris, Andreas H.
In: Leukemia and Lymphoma, Vol. 45, No. 10, 10.2004, p. 2085-2092.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy
AU - Visco, Carlo
AU - Vassilakopoulos, Theodoros P.
AU - Kliche, Kay Oliver
AU - Nadali, Gianpaolo
AU - Viviani, Simonetta
AU - Bonfante, Valeria
AU - Medeiros, L. Jeffrey
AU - Notti, P.
AU - Rassidakis, George Z.
AU - Peethambaram, Prema
AU - Wilder, Richard
AU - Witzig, Thomas
AU - Gianni, Massimo
AU - Bonadonna, Gianni
AU - Pizzolo, Giovanni
AU - Pangalis, Gerassimos A.
AU - Cabanillas, Fernando
AU - Sarris, Andreas H.
PY - 2004/10
Y1 - 2004/10
N2 - Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if ≥ 10 pg/ml. We identified 69 patients with median age of 34 years (range 16-74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and β 2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57%, 36%, and 7% of the population, and their 5-year PFS was 80%, 63%, and 0%, respectively (P <0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.
AB - Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if ≥ 10 pg/ml. We identified 69 patients with median age of 34 years (range 16-74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and β 2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57%, 36%, and 7% of the population, and their 5-year PFS was 80%, 63%, and 0%, respectively (P <0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.
KW - Hodgkin's disease
KW - Interleukin-10
KW - Prognostic factors
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=4544339987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4544339987&partnerID=8YFLogxK
U2 - 10.1080/10428190410001712234
DO - 10.1080/10428190410001712234
M3 - Article
C2 - 15370254
AN - SCOPUS:4544339987
VL - 45
SP - 2085
EP - 2092
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 10
ER -